Skip to content
value.today

ProPhase Labs, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Pharmaceutical: $7 M to $29 M, median $15 MPrice to bookPrice to book of Pharmaceutical: $7 M to $29 M, median $14 M$0 M$8 M$15 M$23 M$31 M

Your own DCF model

A full discounted-cash-flow model of ProPhase Labs, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times ProPhase Labs, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)ProPhase Labs, Inc.Applied toValue (25th to 75th)Companies
Price to sales1.5× / 3.5× / 6.6×—revenue $4 M$7 M to $29 M69
Price to book2.1× / 4.1× / 8.1×—book equity $4 M$7 M to $29 M63

Against its own history

ProPhase Labs, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to May 2026, each against its own median.

Price to sales

1.4×

Now below its median of 2.4×, in the bottom quarter of its range; range 0.7× to 10.8× over 18 months.

0×3×5×8×11×2020202120222023202420252026Price to sales 1×Median 2×

Price to book

1.6×

Now below its median of 2.0×; range 0.2× to 11.1× over 21 months.

0×3×6×8×11×2020202120222023202420252026Price to book 2×Median 2×

As of May 15, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$4 M$-15 M$-8 M$0 M$-8 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$7 M$-53 M$-18 M$1 M$-18 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$35 M$-17 M$-12 M$2 M$-14 M$1 MSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$123 M$18 M$29 M$4 M$25 M$-9 MSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$79 M$6 M$-14 M$4 M$-18 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$15 M$-2 M$-3 M$2 M$-4 M—SEC annual report (10-K, 20-F)